【摘要】 目的探讨重组人血管内皮抑制素注射液(Endostar,YH-16,恩度)联合紫杉醇和波贝(TP方案)治疗晚期非小细胞肺癌(NSCLC)的近期疗效和安全性。方法总结分析中山大学附属第三医院2007年1～12月,经病理组织学或细胞学确诊的ⅢB～Ⅳ期非小细胞肺癌16例接受恩度联合TP(紫杉醇+卡铂)方案治疗。按照WHO标准评价近期疗效,参照Karnofsky(KPS)评分变化评价生活质量(Qualityoflife,QOL),按照WHO抗癌药物毒性反应分度标准评价毒性反应。用药1个周期可评价毒性反应,用药双数周期可评价疗效。结果16例患者均完成2个周期以上方案,总共完成治疗周数为52个周期,平均3.25个/例。总体获CR2例,PR4例,SD6例,PD4例,总体有效率(RR)37.5%,控制率(DCR)75%。16例患者中有6例QOL改善,占37.5%,8例QOL稳定,占50%,2例QOL下降,占12.5%。Ⅲ级以上毒性反应毒性反应包括白细胞下降(25%)、血红蛋白下降(25%)、恶心/腹泻(12.5%)、脱发(12.5%),主要与化疗药物有关。结论恩度联合TP方案治疗晚期NSCLC可使部分患者受益,可以改善患者的生活质量,其毒性低,安全性较好,具有良好的临床应用前景和值得进一步深入研究。更多还原

【Abstract】 Objective To observe the efficacy and safety of endostar combined with taxol and carboplatin (TP) on the advanced non-small cell lung cancer. Methods From January, 2007 to December, 2007, 16 cases of advanced non-small cell lung cancer patients were treated with endostar combined with TP. The efficacy was evaluated strictly after 2 cycles according to WHO criteria, and quality of life (QOL) was evaluated according to Karnofsky performance scores. Results The patients were averagely treated for over 3.25 cycles (2-52 cycles). There were 2 case achieved CR, 4 cases of PR, 6 cases of SD, and 4 cases of PD. The objective response rate (RR) was37.5% (6/16) and disease control rate was75% (12/16). The quality of life of 6 cases were improved (37.5%), 8 cases was stable (50%), and 2 cases dropped (12.5% ). The occurrence rates of G3/4 toxicities were low, including neutropenia (4/16, 25%), thrombocytopenia (4/16, 25% ), nausea/ vomiting (2/16, 12.5% ), and diarrhea (2/16,12.5%), alopecie(2/16, 12.5%). These toxic reactions were mainly related with the chemotherapy. Conclusion Endostar combined with TP were effective for some advanced non-small cell lung cancer cases. Endostar combined with TP was safe and effective, and it is worthy of further clinical observation.更多还原